» Articles » PMID: 37101834

Urine As Matrix for Analysis of Neurofilament Light Chain is Not Suitable to Distinguish Frontotemporal Dementia from Psychiatric Diseases

Overview
Journal Brain Commun
Specialty Neurology
Date 2023 Apr 27
PMID 37101834
Authors
Affiliations
Soon will be listed here.
Abstract

clinical overlap of frontotemporal dementia and primary psychiatric diseases hampers diagnostic distinction, leading to frequent misdiagnosis and diagnostic delay. Neurofilament light chain has shown great potential in CSF and blood for the distinction of frontotemporal dementia from primary psychiatric diseases. Measurement of neurofilament light chain in urine would be even more patient-friendly. We aimed to test the performance of neurofilament light chain urine measurements for diagnostics in frontotemporal dementia and to assess their correlation with serum levels. Fifty-five subjects ( = 19 frontotemporal dementia, = 19 primary psychiatric diseases and = 17 controls) were included with available paired urine and serum samples. All subjects underwent standardized extensive diagnostic assessment. Samples were analysed with the ultrasensitive single molecule array neurofilament light chain assay. Neurofilament light chain group comparisons were performed adjusted for age, sex and geriatric depression scale. In the majority of the cohort, neurofilament light chain concentrations were not detectable in urine ( = 6 samples above lower limit of detection (0.038 pg/ml): = 5 frontotemporal dementia, = 1 primary psychiatric disease). The frequency of a detectable neurofilament light chain level in urine in the frontotemporal dementia group did not differ from psychiatric disorders (Fisher Exact-test = 0.180). In the individuals with detectable urine neurofilament light chain values, there was no correlation between the urine and serum neurofilament light chain levels. As expected, serum neurofilament light chain levels were higher in frontotemporal dementia compared to primary psychiatric diseases and controls ( < 0.001), adjusted for age, sex and geriatric depression scale. Receiver operating characteristic curve analysis of serum neurofilament light chain of frontotemporal dementia versus primary psychiatric diseases showed an area under the curve of 0.978 95% confidence interval 0.941-1.000, < 0.001. Urine is not suitable as a matrix for neurofilament light chain analysis and serum neurofilament light chain is still the most patient-friendly matrix for differentiation between frontotemporal dementia and primary psychiatric diseases.

Citing Articles

Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review.

Squitti R, Fiorenza A, Martinelli A, Brembati V, Crescenti D, Rongioletti M Int J Mol Sci. 2025; 26(1.

PMID: 39795920 PMC: 11719531. DOI: 10.3390/ijms26010061.


Investigation of serum neurofilament light chain as a biomarker in Fabry disease.

Ponleitner M, Gatterer C, Bsteh G, Rath J, Altmann P, Berger T Sci Rep. 2024; 14(1):23033.

PMID: 39362930 PMC: 11449901. DOI: 10.1038/s41598-024-73537-y.

References
1.
Blennow K, Hampel H . CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2(10):605-13. DOI: 10.1016/s1474-4422(03)00530-1. View

2.
Rascovsky K, Hodges J, Knopman D, Mendez M, Kramer J, Neuhaus J . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011; 134(Pt 9):2456-77. PMC: 3170532. DOI: 10.1093/brain/awr179. View

3.
Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, Van den Stock J . Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020; 143(6):1632-1650. PMC: 7849953. DOI: 10.1093/brain/awaa018. View

4.
Del Campo M, Zetterberg H, Gandy S, Onyike C, Oliveira F, Udeh-Momoh C . New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 2022; 18(11):2292-2307. PMC: 9790674. DOI: 10.1002/alz.12643. View

5.
Pijnenburg Y, Verwey N, van der Flier W, Scheltens P, Teunissen C . Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2016; 1(4):505-12. PMC: 4879490. DOI: 10.1016/j.dadm.2015.11.001. View